• Vaccine Name: Japanese encephalitis virus vaccine BV-G-E
• Target Pathogen: Japanese encephalitis virus
• Target Disease: Japanese encephalitis
• Vaccine Ontology ID: VO_0011516
• Type: Recombinant vector vaccine
• Status: Research
• Antigen: Japanese encephalitis virus envelope protein
• E gene engineering:
  • Type: Recombinant vector construction
  • Description: Recombinant pseudotype baculovirus (BV-G-E) was generated by inserting JEV E gene fragment into pFastBac-VSV/G vector. BALB/c mice were immunized with BV-G-E and challenged with JEV wild-type strain. The neutralization antibody, interferon (IFN)- expression and release, and survival rate were analysed and compared with the group of immunized with inactivated vaccine and DNA vaccine (pc-E) encoding the same gene of JEV (Li et al., 2009).
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: Four-week old female BALB/c mice (purchased from the Animal Centre, Institute of Medicine (Hubei Province, China) were randomly divided into seven groups (15 mice per group). Three groups were injected intramuscularly (i.m.) with 100 µl of PBS containing 1 × 10^8, 1 × 10^9 and 1 × 10^10 PFU of BV-G-E, respectively. The other three groups were injected intramuscularly with 100 µl of PBS containing 1 × 10^10 PFU of BV-G-EGFP or 100 µg of pc-E (a DNA vaccine construct expressing E protein) or 100 µl inactivated vaccine. The last group was used as a negative control by intramuscularly injecting 100 µl of PBS. Booster immunizations were identically performed 3 weeks later (Li et al., 2009).
• Challenge Protocol: A subset of immunized mice was intraperitoneally (i.p.) challenged with 105 PFU of wild-type JEV P3 in 0.1 ml at 6 weeks following the initial immunization. Mouse mortality was monitored daily for 3 weeks (Li et al., 2009).
• Efficacy: Researchers constructed a recombinant pseudotype baculovirus encoding the JEV envelope (E) protein and demonstrated that it could elicit high protective immunity in mice. Intramuscular injections of BV-G-E at various doses into mice produced higher levels of JEV-specific neutralizing antibodies, IFN-gamma and better protective efficacy against a lethal challenge with JEV than that of pc-E. Furthermore, BV-G-E could elicit a higher level of cellular immunity response and provide equal protective efficacy against JEV challenge compared to inactivated vaccine (Li et al., 2009).
• Host Ifng (Interferon gamma) response
  • Description: An evident dose-dependent pattern of IFN-gamma production could be observed in mice immunized with BV-G-E. As expected, no significant production of IFN-γ was detected in PBS-inoculated mice. Interestingly, the mean relative IFN-γ mRNA expression in the group of BV-G-EGFP was also significantly higher than that of pc-E vaccinated mice in splenocytes (Li et al., 2009).
  • Detailed Gene Information: Click Here.